Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1291 to 1305 of 1375 results for patients and public

  1. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    In development [GID-TA10995] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    In development [GID-TA11000] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    In development [GID-TA11204] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    In development [GID-TA10996] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    In development [GID-TA11004] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    In development [GID-TA11244] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development [GID-TA10858] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    In development [GID-TA11264] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    In development [GID-TA11041] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    In development [GID-TA11024] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]

    In development [GID-TA11066] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

    This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

    NICE guideline
    Last updated
    25 July 2019
    View recommendations

    Sections for NG61

  15. Social work with adults experiencing complex needs (NG216)

    This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.

    NICE guideline
    Published
    26 May 2022
    View recommendations

    Sections for NG216